Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech, Inc. (Nasdaq: ONCY) is a clinical-stage biotechnology company whose news flow centers on the development of pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Company updates frequently highlight clinical data in metastatic pancreatic cancer, metastatic breast cancer, and gastrointestinal tumors such as anal and colorectal cancers, where pelareorep is being evaluated in combination with chemotherapy and checkpoint inhibitors.
News releases from Oncolytics often cover clinical trial milestones, including results from the GOBLET study in squamous cell anal carcinoma and colorectal cancer, as well as alignment with the U.S. Food and Drug Administration on pivotal trial designs in first-line metastatic pancreatic ductal adenocarcinoma. Investors can also expect announcements about planned registration-directed studies, accelerated approval strategies in indications with no FDA-approved therapies, and translational findings such as tumor-specific T-cell responses in KRAS-mutant metastatic colorectal cancer.
Oncolytics’ news also addresses corporate and regulatory developments, including its proposal to change its jurisdiction of incorporation from Alberta, Canada, to the State of Nevada, its transition to domestic issuer status under SEC rules, and capital markets activities such as at-the-market equity programs. Additional updates describe expansions of the company’s Gastrointestinal Tumor Scientific Advisory Board and appointments of senior leaders in strategy, operations, and biostatistics to support late-stage clinical execution.
This ONCY news page aggregates these press releases and related coverage so readers can follow key developments in pelareorep’s clinical progress, regulatory interactions, intellectual property initiatives, and corporate strategy. It is a useful resource for tracking how new data, advisory board input, and structural changes may influence the company’s oncology pipeline over time.
Oncolytics Biotech (NASDAQ: ONCY) reported its Q1 2025 financial results and clinical progress. The company's lead drug pelareorep showed promising results across multiple cancer types. Key highlights include a 33% objective response rate in anal carcinoma patients and positive safety data in pancreatic cancer trials. The company reported $15.3 million in cash and equivalents, with a net loss of $6.7 million ($0.08 per share) compared to $6.9 million ($0.09 per share) in Q1 2024. R&D expenses decreased to $4.1 million from $5.7 million year-over-year. Oncolytics secured a US$20 million share purchase agreement with Alumni Capital LP to support ongoing clinical development.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy oncology company, has scheduled a conference call and webcast for Wednesday, May 14, 2025, at 4:30 p.m. ET. The event will provide a corporate update and discuss financial results for the first quarter of 2025.
Participants can join through North American toll-free number (888) 510-2154 or international line (437) 900-0527, using conference ID 28038. A webcast replay will be available on the company's Investor Relations page for three months, while a dial-in replay will be accessible for one week using (888) 660-6345 (North America) or (289) 819-1450 (International) with replay code 28038#.
Oncolytics Biotech (NASDAQ: ONCY) announced it will present new data from Cohort 1 of the GOBLET study at the 2025 ASCO Annual Meeting in Chicago. The presentation will showcase pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer.
The data will demonstrate how pelareorep activates immune responses in pancreatic cancer patients. According to Chief Medical Officer Dr. Thomas Heineman, pelareorep has shown encouraging results in multiple studies by engaging the immune system to attack pancreatic cancer tumors, potentially improving outcomes for patients with this hard-to-treat cancer.
The presentation (Abstract #2562) titled 'Role of pelareorep in activating anti-tumor immunity in PDAC' will be delivered as a poster in the Developmental Therapeutics – Immunotherapy session on June 2, 2025.
Oncolytics Biotech (NASDAQ: ONCY) has secured a strategic share purchase agreement (SPA) with Alumni Capital LP to fund the clinical development of pelareorep. The agreement provides Oncolytics with access to up to US$20 million in funding over a 15-month period.
Under the terms, Oncolytics can sell common stock to Alumni at market-based prices, maintaining full control over the timing and amount of sales. The company issued 816,326 commitment shares to Alumni and may issue an additional 816,326 shares pro rata upon purchase notices.
The common shares have received conditional listing approval on the Toronto Stock Exchange (TSX), with required notices filed with Nasdaq. The shares will be offered through a short form base shelf prospectus and prospectus supplement in accordance with securities regulations.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) was featured in a recent H.C. Wainwright Key Opinion Leader event focused on oncolytic immunotherapies in breast and pancreatic cancers. The event highlighted discussions from two prominent experts:
Dr. Martine Piccart, Honorary Professor at Université Libre de Bruxelles and Scientific Director at Institut Jules Bordet, provided insights on HR+/HER2- metastatic breast cancer and emphasized the potential of pelareorep in activating immune responses against cancer.
Dr. Alexander Eggermont, Professor at University Medical Center Utrecht, discussed current treatment standards for pancreatic ductal adenocarcinoma (PDAC) and explored pelareorep's potential impact in treating this resistant form of cancer.
Oncolytics Biotech (NASDAQ: ONCY) reported Q4 and year-end 2024 results, highlighting significant progress in clinical trials. The company's lead candidate, pelareorep, showed strong efficacy in breast, pancreatic, and anal cancer treatments.
Key highlights include promising BRACELET-1 results in HR+/HER2- metastatic breast cancer and GOBLET study data showing a 33% objective response rate in anal cancer. In pancreatic cancer, the GOBLET Cohort 5 safety run-in phase was successfully completed.
Financial results show:
- Cash position of $15.9 million with runway into Q3 2025
- Q4 2024 net loss of $8.0 million ($0.10 per share) vs Q4 2023 net loss of $3.9 million ($0.05 per share)
- R&D expenses at $4.6 million in Q4 2024, down from $4.7 million in Q4 2023
- G&A expenses decreased to $3.9 million from $4.2 million year-over-year
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage immunotherapy company focused on oncology, has scheduled a conference call and webcast for Friday, March 7, 2025, at 8:30 a.m. ET. During this event, the company will provide a corporate update and discuss financial results for the fourth quarter and full year 2024.
Investors and interested parties can access the call through several options:
- North American Toll-Free: (888) 510-2154
- International: (437) 900-0527
- Conference ID: 48422
- RapidConnect option available for joining without operator assistance
A webcast will be available on the Investor Relations page of Oncolytics' website and will remain archived for three months. Additionally, a dial-in replay will be accessible for one week following the call using replay code: 48422#.
Oncolytics Biotech (NASDAQ: ONCY) has achieved significant progress in its cancer immunotherapy development program in 2025. The company received regulatory clearance from Germany's Paul-Ehrlich-Institute to advance enrollment in its pancreatic cancer study (GOBLET Cohort 5), which will include 30 patients testing pelareorep with modified FOLFIRINOX with and without atezolizumab.
At the 2025 ASCO Gastrointestinal Cancers Symposium, the company presented promising clinical data for pelareorep in both anal and pancreatic cancers. Anal cancer patients showed stronger responses to pelareorep plus atezolizumab compared to historical checkpoint inhibitor data. In pancreatic cancer, pelareorep demonstrated favorable safety when combined with modified FOLFIRINOX.
The company anticipates additional data readouts from ongoing gastrointestinal cancer trials and regulatory interactions that could accelerate future trials, particularly in breast cancer and gastrointestinal cancers.
Oncolytics Biotech (NASDAQ: ONCY) has reported significant progress in its clinical programs for pelareorep in early 2025. The company received regulatory clearance from Germany's Paul-Ehrlich-Institute to advance enrollment in its pancreatic cancer study (GOBLET Cohort 5), which will include 30 patients testing pelareorep with modified FOLFIRINOX with and without atezolizumab.
At the 2025 ASCO Gastrointestinal Cancers Symposium, the company presented promising data in both anal and pancreatic cancers. Anal cancer patients receiving pelareorep with atezolizumab showed enhanced responses compared to historical checkpoint inhibitor data. In pancreatic cancer, pelareorep demonstrated favorable safety when combined with modified FOLFIRINOX.
The company expects additional data readouts from ongoing gastrointestinal cancer trials and regulatory interactions that could accelerate future trials in breast cancer and gastrointestinal cancers.
Oncolytics Biotech (NASDAQ: ONCY) reports significant progress in its clinical programs for pelareorep immunotherapy in 2025. The German Paul-Ehrlich-Institute has approved full enrollment for the pancreatic cancer trial (GOBLET Cohort 5) following positive safety review, allowing the study to proceed with 30 patients across two treatment arms.
At ASCO GI 2025, the company presented promising clinical results in both anal and pancreatic cancers. Anal cancer patients receiving pelareorep with atezolizumab showed enhanced responses compared to historical checkpoint inhibitor data. In pancreatic cancer, pelareorep demonstrated favorable safety when combined with modified FOLFIRINOX, with or without atezolizumab.
The company anticipates additional data readouts from ongoing gastrointestinal cancer trials and regulatory interactions that could accelerate future trials toward registration-enabling studies in breast cancer and gastrointestinal cancers.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
